We’re immensely proud of our portfolio. We partner with companies, often in the early stage, to build strong management teams and to ensure our CEOs and entrepreneurs have access to our network and resources to accelerate the advancement of their assets.
The MRCF plays an active, ‘hands on’ role, working closely with the Member Institutes to identify promising opportunities, ‘working them up’, completing due diligence, establishing the start-up company. Importantly, we then guide early-stage investments through the development process to a trade-sale, partnering, next round financing or into stand-alone, growing businesses.The MRCF invests in opportunities originating from its member medical research institutes or research hospitals. Each Member Institute selects a representative for the MRCF’s Investment Review Committee (IRC), the body which provides a peer review assessment of investment proposals.
To date, the MRCF has supported more than 40 promising start-up companies, with over 85 percent of them founded by the MRCF.
Creating the first safe and rapidly effective treatment for peanut allergyView Project
Pathios Therapeutics is an early-stage drug discovery company headquartered in Oxford, UK.View Project
George Medicines is an innovative late-stage drug development company focused on the large, expanding and underserved market for the management of non-communicable diseases (NCDs)View Project
A clinical-stage biotechnology company focussed on the development of ocular implantsView Project
Developing novel anti-fibrotic therapies for the treatment of scarring associated with chronic kidney diseaseView Project
Developing a novel therapy for the treatment of Meibomian Gland DysfunctionView Project
Targeting fibrotic and inflammatory indications associated with type 2 diabetes and metabolic syndrome with an initial focus on liver fibrosisView Project
Developing therapies for patients with cardiac rhythm diseases and heart failure using wireless cardiac stimulationView Project
Developing therapies for respiratory infections in patients with asthma and COPDView Project
Developing therapeutics for the treatment of ophthalmic diseases, including adenoviral conjunctivitisView Project
Developing an imaging technology that will provide intraoperative information to surgeons to assist with the identification of tumour and healthy tissueView Project
A proprietary blood collection tube rapidly providing high quality serum for analysis from all bloods including anti-coagulatedView Project
A clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapyView Project
Vaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solutionView Project
Developing vaccines that target the major virulence factors produced by the bacterium Porphyromonas gingivalis (P gingivalis)View Project
Developing innovative DNA sequencing technologyView Project
Developing antibiotic therapy for cystic fibrosisView Project
Point of care measurement and reporting of Parkinson's diseaseView Project
MecRx is an early stage oncology pharmaceutical company. We are developing inhibitors of the oncoprotein Myc, with the ultimate goal of improving the lives of people with cancer.View Project
Developing innovative therapeutics for the treatment of ophthalmic disordersView Project
Prevention of Contrast Induced Nephropathy (CIN)View Project